The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 09, 2018
Filed:
Sep. 25, 2013
Applicant:
Valorisation-recherche, Limited Partnership, Montreal, CA;
Inventors:
Pascal Chartrand, Montreal, CA;
Emmanuelle Querido, Montreal, CA;
Assignee:
VALORISATION-RECHERCHE, LIMITED PARTNERSHIP, Montreal, CA;
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/55 (2006.01); A61K 31/5375 (2006.01); A61K 31/18 (2006.01); A61K 31/505 (2006.01); A61K 31/40 (2006.01); A61K 31/495 (2006.01); A61K 31/381 (2006.01); A61K 31/352 (2006.01); A61K 31/445 (2006.01); A61K 31/357 (2006.01); A61K 31/4453 (2006.01); A61K 31/4406 (2006.01); A61K 31/454 (2006.01); A61K 31/415 (2006.01); A61K 31/4155 (2006.01); A61K 31/4439 (2006.01); A61K 31/353 (2006.01);
U.S. Cl.
CPC ...
A61K 31/55 (2013.01); A61K 31/18 (2013.01); A61K 31/352 (2013.01); A61K 31/353 (2013.01); A61K 31/357 (2013.01); A61K 31/381 (2013.01); A61K 31/40 (2013.01); A61K 31/415 (2013.01); A61K 31/4155 (2013.01); A61K 31/445 (2013.01); A61K 31/4406 (2013.01); A61K 31/4439 (2013.01); A61K 31/4453 (2013.01); A61K 31/454 (2013.01); A61K 31/495 (2013.01); A61K 31/505 (2013.01); A61K 31/5375 (2013.01);
Abstract
Compounds which inhibit the formation and/or accumulation of RNA foci, such as those due to polynucleotide repeats (e.g., trinucleotide repeats) are described herein. Also described herein are uses of such compounds, such as for the inhibition of the formation and accumulation such RNA foci, as well as for the treatment of polynucleotide repeat disorders (e.g., trinucleotide repeat disorders), such as myotonic dystrophy (e.g., DM1). Such compounds include compounds of formula 1, 1a, 1b, 2, 2a and (3) described herein.